Recent developments in molecular action of antihormones

Journal of Molecular Medicine

Volumn 76, Issue 7, 1998, Pages 512-524

  Fuhrmann, Ulrike ^a,d,e   Parczyk, Karsten ^a   Klotzbücher, Michael ^a   Klocker, Helmut ^b   Cato, Andrew C B ^c,f  

^a BAYER PHARMA AG   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^d EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Antiandrogen; Antiestrogen; Antihormone withdrawal syndrome; Antiprogesterone; Mutant receptors

Indexed keywords

11 [4 (2 DIMETHYLAMINOETHOXY)PHENYL]ESTRADIOL; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTIESTROGEN; ANTIGESTAGEN; CYCLIN D1; ESTROGEN RECEPTOR; FULVESTRANT; GONADORELIN; LILOPRISTONE; MIFEPRISTONE; MUTANT PROTEIN; ONAPRISTONE; PROGESTERONE; PROGESTERONE RECEPTOR; RETINOIC ACID RECEPTOR; SEX HORMONE; STEROID RECEPTOR; TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST CARCINOMA; CRYSTAL STRUCTURE; DRUG MECHANISM; ENDOMETRIOSIS; HORMONE RECEPTOR INTERACTION; LIGAND BINDING; MOUSE; NONHUMAN; PROSTATE CARCINOMA; PROTEIN DOMAIN; PROTEIN FAMILY; REVIEW; UTERUS MYOMA; WITHDRAWAL SYNDROME;

ANIMALS; HORMONE ANTAGONISTS; HUMANS; LIGANDS; RECEPTORS, STEROID; STEROIDS;

EID: 0031812663     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090050245     Document Type: Review

References (166)

1. Evans RM (1988) The steroid and thyroid hormone receptor superfamily. Science 240:889-895
2. Beato M (1989) Gene regulation by steroid hormones. Cell 56: 335-344
3. Beato M, Herrlich P, Schütz, G (1995) Steroid hormone receptor: many actors in search of a plot. Cell 83:851-857
4. Tsui M-J, O'Malley BW (1994) Molecular mechanisms of action of steroid/thyroid hormone receptor superfamily members. Ann Rev Biochem 63:451-486
5. Philibert D, Deraedt R, Teutsch G (1981) RU 486: a potent antiglucocorticoid in vivo (abstract 1463). In: VIIIth International Congress of Pharmacology, Toronto.
6. Herrman W, Wyss R, Rinodel A, Philibert D, Teutsch G, Sakiz E, Baulieu E (1982) Effect d'un steroid antiprogesterone chez, la femme interruption du cycle menstruel de la grosseese au debut. CR Acad Sci 294:933-938
7. Baulieu E (1989) Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor. Science 245: 1351-1357
8. Ulmann A, Teutsch G, Philibert D (1990) RU 486. Sci Am 262:42-48
9. Spitz IM, Bardin CW (1993) Mifepristone (RU 486) - a modulator of progestin and glucocorticoid action. N Engl J Med 329:404-412
10. Spitz IM, Bardin CW (1993) Clinical pharmacology of RU 486 - an antiprogestin and antiglucocorticoid. Contraception 48:403-144
11. Van Look PFA, von Hertzen H (1995) Clinical uses of antiprogestins. Hum Reprod Update 1:19-43
12. Croxatto HB, Salvatierra AM, Fuentealba B, Zurth C, Beier S (1994) Effect of the antiprogestin onapristone on follicular growth in women. Hum Reprod 9:1442-1447
13. Swahn M-L, Kovacs E, Cekan SZ, Aedo A-A, Westlund P (1994) Termination of early pregnancy with ZK 98,734:pharmacokinetic behavior and clinical effect. Hum Reprod 9:57-63
14. Liu JH, Garzo G, Morris S, Stuenkel CA, Ulman A, Yen SSC (1987) Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU 486. J Clin Endocrinol Metab 65:1135-1140
15. Shoupe D, Mishell DJ, Page MA, Madkour H, Spitz IM, Lobo RA (1987) Effects of the antiprogesterone RU 486 in normal women. II. Administration in the late follicular phase. Am J Obstet Gynecol 157:1421-1426
16. Luukkainen T, Heikinheimo O (1988) Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486. Fertil Steril 49:961-963
17. Greene KE, Kettel EM, Yen SSC (1992) Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of the luteal phase of the menstrual cycle: a contraceptive potential. Fertil Steril 58:338-343
18. Croxatto H, Salvatierra AM, Fuentealba B (1993) Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. Hum Reprod 8:201-207
19. Batista M, Cartledge T, Zellnier A, Merino M, Axiotis C, Loriaux E, Nieman E (1992) Delayed endometrial maturation induced by daily administration of the antiprogestin RU486: a potential new contraceptive strategy. Am J Obstet Gynecol 167:60-65
20. Ishward P, Katkam R, Hinduja I, Chwalisz K, Elger W, Puri C (1993) Treatment with a progesterone antagonist ZK 98,299 delays endometrial development without blocking ovulation in bonnet monkeys. Contraception 48:57-70
21. Wolf JP, Hsiu J, Anderson T, Ulmann A, Baulieu EE, Hodgen G (1989) Noneompetitive antiestrogenic effect of RU 486 in blocking the estrogen-stimulated luteinizing hormone surge and the proliferative action of estradiol on endometrium in castrated monkeys. Fertil Steril 52:1055-1060
22. Chwalisz K, Hegele-Hartung C, Fritzemeier K-H, Beier HM, Elger W (1991) Inhibition of the estradiol-mediated endometrial gland formation by the antigestagen onapristone in rabbits: relationship to uterine estroszen receptors. Endocrinology 129:312-322
23. Kettel LM, Murphy AA, Morales AJ, Ulmann A, Baulieu EE, Yen SSC (1996) Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril 65:23-28
24. Murphy A, Kettel M, Morales A, Roberts V, Yen S (1993) Regression of uterine leiomyomata in response to the anti-progesterone RU486. J Clin Endocr Metab 76:513-517
25. Romieu G, Maudelonde T, Ulmann A, Pujol H, Caval G, Khalaf S, Rochefort H (1987) The antiprogestin RU 486 in advanced breast cancer: preliminary clinical trail. Bull Cancer 74:455-461
26. Klijn JAGM, de Jong FH, Bakker GH, Lamberts SWJ, Rodenburg CJ, Alexieva-Eigusch J (1989) Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res 49:2851-2856
27. Robertson, JFR, Wilhser P, Blamey RW (1996) Onapristone, a progesterone receptor antagonist, as first line endocrine therapy in primary breast cancer (poster 515). In: 19th Annual San Antonio Breast Cancer Symposium
28. Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, Lucci E, Stevenson EL (1991) Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 74:861-866
29. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9:1603-1614
30. Conneely OM, Maxwell BE, Toft DO, Schrader WT, O'Malley BW (1987) The A and B forms of the chicken progesterone receptor arise by alternate initiation of translation of a unique mRNA. Biochem Biophys Res Commun 149:493-501
31. Tung L, Mohamed MK, Hoeffler JP, Takimoto GS, Horwitz KB (1993) Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mol Endocrinol 7:1256-1265
32. Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP (1993) Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endoerinol 7:1244-55
33. Allan GE, Tsai SY, Tsai M-J, O'Malley BW (1992) Ligand-dependent conformational changes in the progesterone receptor are necessary for events that follow DNA binding. Proc Natl Acad Sci USA 89:11750-11754
34. Vegeto E, Allan GF, Schrader WT, Tsai M-J, McDonnell DP, O'Malley BW (1992) The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 69:703-713
35. Weigel NL, Beck CA, Estes PA, Prendergast P, Altmann M, Christensen K, Edwards DP (1992) Ligands induce conformational changes in the carboxyl-terminus of progesterone receptors which are detected by a site-directed antipeptide monoclonal antibody. Mol Endocrinol 6:1585-1597
36. Clemm DL, Macy BL, Santiso-Mere D, McDonnell DP (1995) Definition of the critical cellular components which distinguish between hormone and antihormone activated progesterone receptor. J Steroid Biochem Mol Biol 53:487-495
37. Benhamou B, Garcia T, Lerouge T, Vergezac A, Gofflo D, Bigogne C, Chambon P, Gronemeyer H (1992) A single amino acid that determines the sensitivity of progesterone receptors to RU486. Science 255:206-209
38. Wagner BL, Pollio G, Leonhardt S, Wani MC, Lee DY, Imhof MO, Edwards DP, Cook CE, McDonnell DP (1996) 16 Alpha-substituted analogs of the antiprogestin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity. Proc Natl Acad Sci USA 93: 8739-8744
39. Bocquel MT, Ji J, Ylikomi T, Benhamou B, Vergezac A, Chambon P, Gronemeyer H. (1993) Type II antagonists impair the DNA binding of steroid hormone receptors without affecting dimerization. J Steroid Biochem Mol Biol 45:205-215
40. Edwards DP, Altmann M, DeMarzo A, Zhang Y, Weigel NL, Beck CA (1995) Progesterone receptor and the mechanism of action of progesterone antagonists. J Steroid Mol Biol 53: 449-458
41. Neef G, Beier S, Elger W, Henderson D; Wiechert R (1984) New steroids with antiprogestational and antiglucocorticoid activities. Steroids 44:349-372
42. Klein-Hitpass L, Cato ACB, Henderson D, Ryffel GU (1991) Two types of antiprogestines identified by their differential action in transcriptionally active extracts from T47D cells. Nucleic Acids Res 19:1227-1233
43. Vaßen L, Klotzbücher M, Ulber V, Ryffel GU, Klein-Hitpass L (1994) Regulation of progesterone receptor activity in cell culture systems and cell-free transcription. In: Fusenig NE, Graf H (eds) Cell culture in pharmaceutical research. Proceedings of the Schering Research Foundation, vol 11. Springer, Berlin Heidelberg New York, pp 267-297
44. Bocquel MT, Ji J, Ylikomi T, Benhamou B, Vergezac A, Chambon P, Gronemeyer H (1993) Type II antagonists impair the DNA binding of steroid hormone receptors without affecting dimerization. J Steroid Biochem Mol Biol 45: 205-215
45. Chwalisz K, Stöckemann K, Fuhrmann U, Fritzemeier KH, Einspanier A, Garfield RE (1995) Mechanism of action of antiprogestins in the pregnant uterus. In: Henderson D, Philibert D, Roy AK, Teutsch G (eds) Annuals of the New York Academy of Science: steroid receptors and antihormones. IX International Congress on Hormonal Steroid, Dallas USA, pp S202-224
46. El-Ashry D, Onate SA, Nordeen SK, Edwards DP (1990) Human progesterone receptor complexed with the antagonist RU 486 binds to hormone response elements in a structurally altered form. Mol Endocrinol 3:1545-1558
47. Delabre K, Guichon-Mantel A, Milgrom E (1993) In vivo evidence against the existence of antiprogestines disrupting receptor binding to DNA. Proc Natl Acad Sci USA 90:4421-4425
48. Truss M, Bartsch J, Beato M (1994) Antiprogestines prevent progesterone receptor binding to hormone responsive elements in vivo. Proc Natl Acad Sci USA 91:11333-11337
49. Zhang Y, Beck CA, Poletti A, Edwards DP, Weigel NL (1995) Identification of a group of Ser-Pro motif hormone-inducible phosphorylation sites in the human progesterone receptor. Mol Endocrinol 9:1029-1040
50. Sheridan PL, Evans RM, Horwitz KB (1989) Phosphotryptic peptide analysis of human progesterone receptors. J Biol Chem 264:6520-6528
51. Zhang Y, Bai W, Allgood VE, Weigel NL (1994) Multiple signaling pathways activate the chicken progesterone receptor. Mol Endocrinol 8:577-584
52. Takimoto GS, Tasset DM, Eppert AC, Horwitz KB (1992) Hormone-induced progesterone receptor phosphorylation consists of sequential DNA-independent and DNA-dependent stages: analysis with zinc finger mutants and the progesterone antagonist ZK98299. Proc Natl Acad Sci USA 89: 3050-3054
53. Beck CA, Zhang Y, Weigel NL, Edwards DP (1996) Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor. J Biol Chem 271:1209-1217
54. Beck CA, Weigel NL, Mover ML, Nordeen SK, Edwards DP (1992) The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways Proc Natl Acad Sci USA 90:4441-4445
55. Sartorius CA, Tung L, Takimoto GS, Horwitz KB (1993) Antagonist-occupied human progesterone receptors hound to DNA are functionally switched to transcriptional agonists by cAMP. J Biol Chem 268:9262-9266
56. Sartorius CA, Groshong SD, Miller LA, Powell RL, Tung L, Takimoto GS, Horwitz KB (1994) New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res 54:3868-3877
57. Gravanis A, Schaison G, George M (1985) Endometrial and pituitary responses to the steroidal antiprogestin RU486 in postmenopausal women. J. Clin Endocr Metab 60:156-163
58. Michna H, Schneider MR, Nishino Y, El Etreby MF (1989) The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death. J Steroid Biochem 34:447-453
59. Schneider MR, Michna H, Nishino Y, Henderson D (1991) Antitumor activity and mechanism of action of the progesterone antagonist in experimental breast cancer In: Masobrio M, Menato G, Cassoni P, Simonetta M (eds) Attualita endocrine in oncologia ginecologica e in medicina del riproduzione. Moduzzi, Bologna, pp 90-105
60. Horwitz KB (1992) The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? Endocr Rev 13:146-163
61. 1 Breast Cancer Res Treat 17:155-156
62. Musgrove EA, Sutherland RL (1993) Effects of the progestin antagonist RU 486 on T-47D cell cycle kinetics and cell cycle regulatory genes. Biochem Biophys Res Commun 195: 1184-1190
63. Musgrove E, Hamilton J, Lee C, Sweeny K, Watts C, Sutherland R (1993) Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cel Biol 13:3577-3587
64. Musgrove, EA, Lee CSL, Cornish AL, Swarbrick A, Sutherland RL (1997) Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. Mol Endocrinol 11:54-66
65. Heikinheimo O, Hsiu J-G, Gordon K, Kim S, Williams RF, William EG, Hodgen GD (1996) Endometrial effects of RU 486 in primates-antiproliferative action and increased cyclin-B expression. J Steroid Biochem 59:179-190
66. Berry M, Metzger D, Chambon P (1990) Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 9:2811-2818
67. Howell A, Dodwell DJ, Laidlaw I, Anderson H, Anderson E (1990) Tamoxifen as an agonist for metastatic breast cancer. In: Goldhirsch A (ed) Endocrine therapy of breast cancer. Springer. Berlin Heidelberg New York, pp 49-58
68. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339:1-15
69. Patterson JS (1981) Clinical aspects and development of anti-estrogen therapy: a review of the endocrine effects of tamoxifen in animals and man. J Endocrinol 89:323-329
70. Magriples A, Naftolin F, Scharz PE (1993) High grade endometrial carcinoma in tamoxifen treated breast cancer patients. J Clin Oncol 11:485-490
71. Wakeling AE, Bowler J (1987) Steroidal pure antiestrogens. J Endocrinol 112:R7-R10
72. Wakeling AE, Dukes M, Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867-3873
73. Van de Velde P, Nique F, Bouchoux F, Brémaud J, Hameau M-C, Lucas D, Moratille C, Viel S, Philibert D, Teutsch G (1994) RU 58 668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice. J Steroid Biochem Mol Biol 48:187-196
74. Von Angerer E, Biberger C, Leichtl S (1995) Studies on heterocycle based pure antagonists. Ann NY Acad Sci 761:176-191
75. Ignar-Trowbridge DM, Nelson KG, Bidwell MC, Curtis SW, Washburn TF, McLachlan JA, Korach K (1992) Coupling of dual signalling pathways: epidermal growth factor action involves the estrogens receptor. Proc Natl Acad Sci USA 89: 4658-1662
76. Katzenellenbogen BS, Montano MM, Le Goff P, Schodin DJ, Lee Kraus W, Bhardwaj B, Fujimoto N (1995) Antiestrogens: mechanisms and actions in target cells. J Steroid Biochem. Mol Biol 53:387-393
77. Bunone G, Briand P-A, Miksicek J, Picard D (1996) Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 15:2174-2183
78. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon, P (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494
79. Reese JC, Katzenellenbogen B (1991) Differential DNA-binding abilities of estrogen receptor occupied with two classes of antiestrogens: studies using human estrogen recpeptor overexpressed in mammalian cells. Nucleic Acids Res 19:6595-6602
80. Metzger D, Berry M, Ali S, Chambon P (1995) Effect of antagonists on DNA binding properties of the human estrogen receptor in vitro and in vivo. Mol Endocrinol 9:579-590
81. Pink JJ, Jordan VC (1996) Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56:2321-2330
82. Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG (1990) Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci 87: 6883-6887
83. Pham TA, Elusion JF, Nawaz Z, McDonell D, Tsai M-J, O'Malley BW (1991) Antiestrogen can establish nonproductive receptor complexes and alter chromatin structure at target enhancers. Proc Natl Acad Sci 88:3125-3129
84. Reese JC, Katzenellenbogen BS (1991) Differential DNA-binding abilities of estrogen receptor occupied with two classes of antiestrogens: studies using human estrogen receptor overexpressed in mammalian cells. Nucleic Acids Res 19: 6595-6602
85. Arbuckle ND, Dauvois S, Parker MG (1992) Effects of antioestrogens in the DNA binding activity of estrogen receptors in vitro. Nucleic Acids Res 20:3839-3844
86. Dauvois S, Danielian PS, White R, Parker MG (1992) Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci 89:4037-4041
87. McClelland RA, Gee JMW, Francis AB, Robertson JFR, Blamey RW, Wakeling AE, Nicholson RI (1996) Short-term effects of pure anti-estrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer. Eur J Cancer 32A:413-416
88. Kiang DT, Kollander RE, Thomas T, Kennedy BJ (1989) Upregulation of estrogen receptors by nonsteroidal antiestrogens in human breast cancer. Cancer Res 49:5312-5316
89. Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H (1993) Upregulation of estrogen receptor by tamoxifen in human breast cancer. Cancer 71:1266-1276
90. Jin L, Borrás M, Lacroix M, Legros N, Leclercq G (1995) Antiestrogenic activity of two 11-estradiol derivatives on MCF-7 breast cancer cells. Steroids 60:512-518
91. Parczyk K, Madjno R, Angerer EV, Schneider MR (1995) Various pure antiestrogens downregulate the HR while partial agonists do not. In: 12th International Symposium of the Journal of Steroid Biochemistry and Molecular Biology, 21-24 May 1995, Berlin
92. Dauvois S, White R, Parker MG (1993) The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106:1377-1388
93. Stein B, Yang MX (1995) Repression of the interleukin-6 promoter by estroizen receptor is mediated by NF-κB and C/EBP. Mol Cell Biol 15:4971-4979
94. Galien R, Evans HF, Garcia T (1996) Involvement of CCA-AT/Enhancer-binding protein and nuclear factor-κB binding sites in interleukin-6 promoter inhibition by estroens. Mol Endocrinol 10:713-722
95. Webb P, Lopez GN, Uht RM, Kushner PJ (1995) Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell specific estrogen like effects of antiestrogens. Mol Endocrinol 9:443-456
96. Yang NN, Venugopalan M, Hardikar S, Glasebrook A (1996) Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifen. Science 273: 1222-1225
97. Osborne CK, Coronado-Heinsohn EB, McCue BL, Wakeling A, Nicholson RI ( 1995) Comparison of the effects of a steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87:746-750
98. Nicholson RI, Francis AB, Kyne S, Gee JMW (1996) Properties and mode of action of pure antiestrogens in breast cancer in vitro. Breast 5:175-180
99. R-1. Cancer Res 54:1587-1595
100. Clarke R, Brünner N (1995) Cross-resitance and molecular mechanisms in antiestrogen resistance. Endocr Rel Cancer 2: 59-72
101. Nicholson RI, Gee JMW, Bryant S, Francis AB, McClelland RA, Knowlden J, Wakeling AE, Osborne CK (1996) Pure antiestrogens-the most important advance in the endocrine therapy of breast cancer since 1896? Ann NY Acad Sci 784: 325-335
102. Parker SL, Tong T, Bolden S, Wingo P A (1996) Cancer statistics. CA Cancer J Clin 46:5-27
103. Huggins C, Hodges CV (1941) Studies on prostatic cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297
104. Veterans Administration Co-operative Urological Research Group (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124:1010-1017
105. The Leuprolide Study Group (1984) Leuprolide versus diethylstilbesterol for metastatic prostate cancer. N Engl J Med 311:1281-1286
106. Corbin A (1982) From contraception to cancer: a review of the therapeutic applications of LHRH analogs as antitumor agents. Yale J Biol Med 55:27-47
107. Labrie C, Belanger A, Labrie F (1988) Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology, 123:1412-1417
108. Labrie C, Simard J, Zhao HF, Belanyer A, Pelletier G, Labrie F (1989) Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocr Soc 124:2745-2754
109. Labrie F, Belanger A, Dupont A, Luu The V, Simard J, Labrie C (1993) Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med 16:475-492
110. Labrie F, Belanger A, Simard J, Labrie C, Dupont A (1993) Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy. Cancer 71:1059-1067
111. Labrie F, Lurthy I, Veilleux R, Simard J, Belanger A, Dupont A (1987) New concepts on the androgen sensitivity of prostate cancer. Prog Clin Biol Res 243A: 145-172
112. Labrie F, Dupont A, Belanger A, Giguere M, Lacoursiere Y, Emond J, Monfette G, Bergeron V (1985) Combination therapy with flutumide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem 23:833-841
113. Labrie F, Dupont A, Belanger A, Lachance R, Giguere M (1985) Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations. BMJ 291:369-370
114. Crawford ED, Blumenstein BA, Goodman PJ, Davis MA, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA (1990) Leuprolide with and without flutamide in advanced prostate cancer. Cancer 66:1039-1044
115. Crawford ED (1990) Combination studies with leuprolide. Eur Urol 3:30-33
116. Prostate Cancer Trialists' Group (1995) Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346:265-269
117. Van der Kwast T, Schalken J, Ruizeveld de Winter J, Van Vroonhoven C, Mulder E, Boersma W, Trapman J (1991) Androgen receptors in endocrine therapy-resistant human prostate cancer. Int J Cancer 48:189
118. Sadi MV, Walsh PC, Barrack ER (1991) Immunohistochemical study of androgen receptors in metastatic prostate cancer - comparison of receptor content and response to hormonal therapy. Cancer 67:3057-3064
119. Sadi MV, Barrack ER (1992) Image analysis of androgen receptor immunostaining in metastatic prostate cancer: heterogeneity as a predictor of response to hormonal therapy. Cancer 71:2574-2580
120. Ruizveld de Vinter JA, Trapman J, Brinkmann AO, Boersma WJA, Mulder E, Schroeder FH, Claassen E, and Van der Kwast TH (1990) Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry. J Pathol 161:329-332
121. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A (1996) Androgen receptor status of lymph node metastases from prostatic carcinoma. Prostate 28:129-135
122. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A (1995) Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 55:3068-3072
123. Koivisto P, Hyytinen E, Palmberg C, Tammela T, Visakorpi T, Isola J, Kallioniemi OP (1995) Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. Am J Pathol 147:1608-1614
124. Visakorpi T, Hyytinen E, Hoivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genet 4:401-406
125. Kokontis J, Takakura K, Hay N, Liao S (1994) Increased androgen receptor activity and altered c-myc expression in prostate cancer cells alter long-term androgen deprivation. Cancer Res 54:1566-1573
126. 24→18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun 198:74-80
127. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J (1993) Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Molec Biol 46:759-765
128. Taplin M-E, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP (1995) Mutation of the androgen receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398
129. Tilley WD, Buchanan G, Hickey TE, Bentel JM (1996) Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2:277-285
130. Culig Z, Hobisch A, Cronauer MV, Cato ACB, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H (1993) Mutant receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol 7:1541-1550
131. Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Issac WB, Brown TR, Barrack ER (1992) Androgen-receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 89:6319-6323
132. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S (1994) Frequent detection of codon 877 mutation in the androgen-receptor gene inadvanced prostate cancers. Cancer Res 54:2861-2864
133. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, Van Rooij HC, Trapman J, Brinkmann AO, Mulder E (1990) A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173:534-540
134. Ris-Stalpers C, Verleun-Mooijman MCT, Trapman J, Brinkmann AO (1993) Threonine on amino acid position 868 in the human androgen receptor is essential for androgen binding specificity and functional activity. Bioxhem Biophys Res Commun 196:173-180
135. Peterziel H, Culig Z, Stober J, Hobisch A, Radmayr C, Bartsch G, Klocker H, Cato ACB (1995) Mutant androgen receptors in prostatic tumours distinguish between amino acid-sequence requirements for transactivation and ligand binding. Int J Cancer 63:544-550
136. Renaud J-P, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, Moras, D (1995) Crystal structure of the RARγ-ligand binding domain bound to all-trans retinoic acid. Nature 378:681-689
137. Wurtz J-M, Bourguet W, Renaud J-P, Vivat V, Chambon P, Moras D, Gronemeyer H (1996) A canonical structure for the ligand-binding domain of nuclear receptor. Nat Struct Biol 3: 87-94
138. Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras, D (1995) Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α. Nature 375:377-382
139. Wagner RL, Apriletti JW, McGrath ME, West BL, Baxter JD, Fletterick RJ (1995) A structural role of hormone in the thyroid hormone receptor. Nature 378:690-697
140. Kelly WK, Scher HI (1993) Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 149:607-609
141. Scher HI, Kelly WK (1993) Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566-1572
142. Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A, Steinberg S, Figg WD, Linehan WM, Myers CE (1994) Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. J Natl Cancer Inst 86:222-227 (published erratum appears in J Natl Cancer Inst 86:463)
143. Figg WD, Sartor O, Cooper MR, Thibault A, Bergan RC, Dawson N, Reed E, Myers CE (1995) Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med 98:412-114
144. Dupont A, Gomez JL, Cusan L, Koutsilieris M, Labrie F (1993) Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 150:908-913
145. Moul JW, Srivastava S, McLeod DG (1995) Molecular implications of the antiandrogen withdrawal syndrome. Semin Urol 13:157-163
146. Small EJ, Carroll PR (1994) Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 43:408-410
147. Akakura K, Akimoto S, Ohki T, Shimazaki J (1995) Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate. Urology 45:700-704
148. Dawson NA, McLeod DG (1995) Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol 153:1946-1947
149. DeFriend DJ, Howell A (1994) Tamoxifen withdrawal responses-chance observations or clinical clues to antioestrogen resistance. Breast 3:199-201
150. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD (1993) Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 71:2782-2790
151. Bruchovsky N, Snoek R, Rennie PS, Akakura K, Goldenberg LS, Gleave M (1996) Control of tumor progression by maintenance of apoptosis. Prostate Suppl 6:13-21
152. Bruchovsky N, Goldenberg SL, Rennie PS, Gleave M (1995) Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma. Urologe A34:389-392
153. DeAntoni E, Crawford ED (1995) Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma. Urologe A34:382-388
154. McLeod DG, Kolvenbag GJ (1996) Defining the role of antiandrogens in the treatment of prostate cancer. Urology 47:85-89
155. Takahashi H, Furusato M, Allsbrook Jr WC, Nishii H, Wakui S, Barrett JC, Boyd J (1995) Prevalence of androgen receptor gene mutation in latent prostatic carcinomas from Japanese men. Cancer Res 55:1621-1624
156. Gravanis A, Schaison G, George M (1985) Endometrial and pituiary responses to the sterodal antiprogestin R7486 in postmeriopansal women. J Clin Endocr Metab 60:156-63
157. Clarke R, Brünner N (1996) Acquired estrogen independence and antiestrogen resistance in breast cancer. Estrogen receptor driven phenotypes? Trends Endocrinol Metab 7:291-301
158. Gauthier S, Caron B, Cloutier J, Dory YL, Favre A, Larouche D, Mailhot J, Quellet C, Schwerdtfeger A, Leblanc G, Martel C, Simard J, Merand Y, Belanger A, Labrie C, Labrie F (1997) (S)-(+)-4-[7-(2,2-Dimethyl-1-oxopropoxy)-4-methyl-2-]4-[2-(1-piperidinyl)- ethoxy[phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen. J Med Chem 40:2117-2122
159. Zwijsen RML. Wientjens E, Klompmaker R, Van de Sman J, Bernards R, Michalides RJAM (1997) CDK-independent activation of estrogen receptor by cyclin DI. Cell 88: 405-415
160. Kuiper GJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-Å (1996) Cloning of a novel estrogen receptor expresed in rat prostate and ovary. Proc Natl Acad Sci 93:5925-5930
161. Mosselman S, Polman J, Dijkema R (1996) ERβ: identification and characterization of a novel estrogen receptor. FEBS Lett 392:49-53
162. Von Angerer E, Biberger C, Holler E, Koop R, Leichtl S (1994) 1-Carbamoylalkyl-2-phenylindoles: relationship between side chain structure and estrogen antagonism. J Steroid Biochem Mol Biol 49:51-62
163. Nédélec L, Bouton MM, Nique F, Teutsch G, Van de Velde P, Philibert D (1989) 11β-Aminoalkoxyphenylestradiols, a new series of potent antiestrogens (abstract 34P). In: 9th International Symosium of J Steroid Biochem, Las Palmas
164. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Lung L (1996) Nuclear receptor coactivators and corepressors. Mol Endocrinol 10:1167-1177
165. Smith CL, Nawaz Z, O'Malley BW (1997) Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen. 4-hydroxytamoxifen. Mol Endocrinol 11:657-666
166. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz, KB (1997) The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coaetivalor L7/SPA and the compressors N-CoR and SMRT. Mol Endocrinol 11:693-705